Verona Pharma PLC
NASDAQ:VRNA

Watchlist Manager
Verona Pharma PLC Logo
Verona Pharma PLC
NASDAQ:VRNA
Watchlist
Price: 36.32 USD -1.65%
Market Cap: 3B USD
Have any thoughts about
Verona Pharma PLC?
Write Note

Intrinsic Value

VRNA's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one VRNA stock under the Base Case scenario is 16.3 USD. Compared to the current market price of 36.32 USD, Verona Pharma PLC is Overvalued by 55%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

VRNA Intrinsic Value
16.3 USD
Overvaluation 55%
Intrinsic Value
Price
Base Case Scenario

Valuation Backtest
Verona Pharma PLC

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for VRNA cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about VRNA?
Bearish
Neutral
Bullish
Discover Undervalued Stocks
Pharmaceuticals Industry

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about Verona Pharma PLC

Provide an overview of the primary business activities
of Verona Pharma PLC.

What unique competitive advantages
does Verona Pharma PLC hold over its rivals?

What risks and challenges
does Verona Pharma PLC face in the near future?

Has there been any significant insider trading activity
in Verona Pharma PLC recently?

Summarize the latest earnings call
of Verona Pharma PLC.

What significant events have occurred
in Verona Pharma PLC over the past months?

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Verona Pharma PLC.

Provide P/S
for Verona Pharma PLC.

Provide P/E
for Verona Pharma PLC.

Provide P/OCF
for Verona Pharma PLC.

Provide P/FCFE
for Verona Pharma PLC.

Provide P/B
for Verona Pharma PLC.

Provide EV/S
for Verona Pharma PLC.

Provide EV/GP
for Verona Pharma PLC.

Provide EV/EBITDA
for Verona Pharma PLC.

Provide EV/EBIT
for Verona Pharma PLC.

Provide EV/OCF
for Verona Pharma PLC.

Provide EV/FCFF
for Verona Pharma PLC.

Provide EV/IC
for Verona Pharma PLC.

Show me price targets
for Verona Pharma PLC made by professional analysts.

What are the Revenue projections
for Verona Pharma PLC?

How accurate were the past Revenue estimates
for Verona Pharma PLC?

What are the Net Income projections
for Verona Pharma PLC?

How accurate were the past Net Income estimates
for Verona Pharma PLC?

What are the EPS projections
for Verona Pharma PLC?

How accurate were the past EPS estimates
for Verona Pharma PLC?

What are the EBIT projections
for Verona Pharma PLC?

How accurate were the past EBIT estimates
for Verona Pharma PLC?

Compare the revenue forecasts
for Verona Pharma PLC with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Verona Pharma PLC and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Verona Pharma PLC against its competitors.

Analyze the profit margins
(gross, operating, and net) of Verona Pharma PLC compared to its peers.

Compare the P/E ratios
of Verona Pharma PLC against its peers.

Discuss the investment returns and shareholder value creation
comparing Verona Pharma PLC with its peers.

Analyze the financial leverage
of Verona Pharma PLC compared to its main competitors.

Show all profitability ratios
for Verona Pharma PLC.

Provide ROE
for Verona Pharma PLC.

Provide ROA
for Verona Pharma PLC.

Provide ROIC
for Verona Pharma PLC.

Provide ROCE
for Verona Pharma PLC.

Provide Gross Margin
for Verona Pharma PLC.

Provide Operating Margin
for Verona Pharma PLC.

Provide Net Margin
for Verona Pharma PLC.

Provide FCF Margin
for Verona Pharma PLC.

Show all solvency ratios
for Verona Pharma PLC.

Provide D/E Ratio
for Verona Pharma PLC.

Provide D/A Ratio
for Verona Pharma PLC.

Provide Interest Coverage Ratio
for Verona Pharma PLC.

Provide Altman Z-Score Ratio
for Verona Pharma PLC.

Provide Quick Ratio
for Verona Pharma PLC.

Provide Current Ratio
for Verona Pharma PLC.

Provide Cash Ratio
for Verona Pharma PLC.

What is the historical Revenue growth
over the last 5 years for Verona Pharma PLC?

What is the historical Net Income growth
over the last 5 years for Verona Pharma PLC?

What is the current Free Cash Flow
of Verona Pharma PLC?

Discuss the annual earnings per share (EPS)
trend over the past five years for Verona Pharma PLC.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Verona Pharma PLC

Current Assets 364.3m
Cash & Short-Term Investments 336m
Receivables 12.5m
Other Current Assets 15.7m
Non-Current Assets 17.6m
Long-Term Investments 15m
PP&E 2m
Intangibles 545k
Current Liabilities 28m
Accounts Payable 6.8m
Accrued Liabilities 19.1m
Other Current Liabilities 2m
Non-Current Liabilities 223.4m
Long-Term Debt 120m
Other Non-Current Liabilities 103.4m
Efficiency

Earnings Waterfall
Verona Pharma PLC

Revenue
5.6m USD
Cost of Revenue
-543k USD
Gross Profit
5.1m USD
Operating Expenses
-160.5m USD
Operating Income
-155.4m USD
Other Expenses
1.7m USD
Net Income
-153.7m USD

Free Cash Flow Analysis
Verona Pharma PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

VRNA Profitability Score
Profitability Due Diligence

Verona Pharma PLC's profitability score is 12/100. The higher the profitability score, the more profitable the company is.

12/100
Profitability
Score

Verona Pharma PLC's profitability score is 12/100. The higher the profitability score, the more profitable the company is.

VRNA Solvency Score
Solvency Due Diligence

Verona Pharma PLC's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Negative Net Debt
Long-Term Solvency
Low D/E
50/100
Solvency
Score

Verona Pharma PLC's solvency score is 50/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

VRNA Price Targets Summary
Verona Pharma PLC

Wall Street analysts forecast VRNA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VRNA is 39.08 USD with a low forecast of 31.82 USD and a high forecast of 52.5 USD.

Lowest
Price Target
31.82 USD
12% Downside
Average
Price Target
39.08 USD
8% Upside
Highest
Price Target
52.5 USD
45% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for VRNA?

Click here to dive deeper.

Dividends

Verona Pharma PLC
does not pay dividends
Shareholder Yield

Current shareholder yield for VRNA is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Ownership

VRNA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

VRNA News

Profile

Verona Pharma PLC Logo
Verona Pharma PLC

Country

United Kingdom

Industry

Pharmaceuticals

Market Cap

3B USD

Dividend Yield

0%

Description

Verona Pharma Plc operates as a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. The firm's product candidate, ensifentrine, is an investigational, inhaled, dual inhibitor of the enzyme's phosphodiesterase 3 and 4 (PDE3 and PDE4), which is designed to act as both a bronchodilator and an anti-inflammatory agent. The firm is developing ensifentrine in three formulations for mostly used inhalation devices, such as nebulizer, dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The company is evaluating nebulized ensifentrine in a Phase III clinical program ENHANCE (Ensifentrine as an inhaled nebulized chronic obstructive pulmonary disease (COPD) therapy) for COPD maintenance treatment. Verona Pharma, Inc. is its wholly owned subsidiary.

Contact

London
Riverside, 3 More London Place
+114402032834200.0
www.veronapharma.com

IPO

2005-03-30

Employees

24

Officers

President, CEO & Executive Director
Dr. David S. Zaccardelli Pharm.D.
Chief Financial Officer
Mr. Mark W. Hahn
Chief Medical Officer
Dr. Kathleen A. Rickard M.D.
General Counsel
Mr. Andrew Fisher
Director of Communications
Ms. Victoria Stewart
VP of Sales, Marketing & Training
Mr. Matthew Casbon
Show More
Senior Vice President of Human Resources
Ms. Ostra Jewell
Chief Development Officer
Dr. Tara Rheault M.P.H., Ph.D.
Chief Commercial Officer
Mr. Christopher Martin
Senior Vice President of Regulatory Affairs
Ms. Caroline Diaz
Show Less

See Also

Discover More
What is the Intrinsic Value of one VRNA stock?

The intrinsic value of one VRNA stock under the Base Case scenario is 16.3 USD.

Is VRNA stock undervalued or overvalued?

Compared to the current market price of 36.32 USD, Verona Pharma PLC is Overvalued by 55%.

Back to Top